Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2014, Article ID 536856, 5 pages
http://dx.doi.org/10.1155/2014/536856
Case Report

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

1SEEBMO, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, Portugal
2Genetics & Arthritis Research Group (GARG), Institute for Molecular and Cell Biology (IBMC), 4150 Oporto, Portugal
3Grupo de Epidemiologia e Genética Humana do Departamento de Biologia da Universidade dos Açores, 9500 Ponta Delgada, Portugal
4Rheumatology Research Unit, Molecular Medicine Institute, Lisbon, Portugal
5Serviço de Medicina Interna, Hospital de Santo Espírito da Ilha Terceira, 9700 Angra do Heroísmo, Portugal
6Merck Sharp & Dohme, 1135 Brussels, Belgium
7University of Queensland, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, QLD 4192, Australia

Received 12 August 2014; Accepted 14 October 2014; Published 11 November 2014

Academic Editor: Mario Salazar-Paramo

Copyright © 2014 Jácome Bruges-Armas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Zhang, M. Doherty, T. Bardin et al., “European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 563–570, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Resnick and C. Pineda, “Vertebral involvement in calcium pyrophosphate dihydrate crystal deposition disease. Radiographic-pathological correlation,” Radiology, vol. 153, no. 1, pp. 55–60, 1984. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Reginato, F. Valenzuela, V. Martinéz, G. Passano, and S. Daza, “Polyarticular and familial chondrocalcinosis,” Arthritis and Rheumatism, vol. 13, no. 3, pp. 197–213, 1970. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Okazaki, T. Saito, T. Mitomo, and Y. Siota, “Pseudogout: clinical observations and chemical analyses of deposits,” Arthritis & Rheumatism, vol. 19, supplement 3, pp. 293–305, 1976. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Bruges-Armas, A. R. Couto, A. Timms et al., “Ectopic calcification among families in the Azores: clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis,” Arthritis and Rheumatism, vol. 54, no. 4, pp. 1340–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Zhang, M. Doherty, E. Pascual et al., “EULAR recommendations for calcium pyrophosphate deposition. Part II: management,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 571–575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Gabay, C. Lamacchia, and G. Palmer, “IL-1 pathways in inflammation and human diseases,” Nature Reviews Rheumatology, vol. 6, no. 4, pp. 232–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. So, T. de Smedt, S. Revaz, and J. Tschopp, “A pilot study of IL-1 inhibition by anakinra in acute gout,” Arthritis Research and Therapy, vol. 9, article R28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. So, M. de Meulemeester, A. Pikhlak et al., “Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study,” Arthritis & Rheumatism, vol. 62, no. 10, pp. 3064–3076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. McGonagle, A. L. Tan, J. Madden, P. Emery, and M. F. McDermott, “Successful treatment of resistant pseudogout with anakinra,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 631–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Announ, G. Palmer, P.-A. Guerne, and C. Gabay, “Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure,” Joint Bone Spine, vol. 76, no. 4, pp. 424–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Baraliakos and J. Braun, “Biologic therapies for spondyloarthritis: what is new?” Current Rheumatology Reports, vol. 14, no. 5, pp. 422–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. K. J. Aaltonen, L. M. Virkki, A. Malmivaara, Y. T. Konttinen, D. C. Nordström, and M. Blom, “Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis,” PLoS ONE, vol. 7, no. 1, Article ID e30275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Franchi, N. Warner, K. Viani, and G. Nuñez, “Function of Nod-like receptors in microbial recognition and host defense,” Immunological Reviews, vol. 227, no. 1, pp. 106–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. F. S. di Giovine, S. E. Malawista, E. Thornton, and G. W. Duff, “Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular distribution,” Journal of Clinical Investigation, vol. 87, no. 4, pp. 1375–1381, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. A. D. Woolf and P. A. Dieppe, “Mediators of crystal-induced inflammation in the joint,” British Medical Bulletin, vol. 43, no. 2, pp. 429–444, 1987. View at Google Scholar · View at Scopus
  19. H. M. Burt and J. K. Jackson, “The priming action of tumour necrosis factor-alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophils activated by inflammatory microcrystals,” Clinical and Experimental Immunology, vol. 108, no. 3, pp. 432–437, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Hachicha, P. H. Naccache, and S. R. McColl, “Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis,” Journal of Experimental Medicine, vol. 182, no. 6, pp. 2019–2025, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. G. R. Lichtenstein, “Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response,” Therapeutic Advances in Gastroenterology, vol. 6, no. 4, pp. 269–293, 2013. View at Publisher · View at Google Scholar · View at Scopus